S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
The Stock That's Brining Lithium Back To America! (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
The Stock That's Brining Lithium Back To America! (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
The Stock That's Brining Lithium Back To America! (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
The Stock That's Brining Lithium Back To America! (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
NASDAQ:AXNX

Axonics (AXNX) Stock Forecast, Price & News

$50.85
+1.68 (+3.42%)
(As of 06/7/2023 ET)
Compare
Today's Range
$49.16
▼
$50.96
50-Day Range
$48.02
▼
$60.21
52-Week Range
$46.57
▼
$79.92
Volume
638,030 shs
Average Volume
648,585 shs
Market Capitalization
$2.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.44
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

Axonics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
54.3% Upside
$78.44 Price Target
Short Interest
Bearish
8.26% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$1.34 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.40) to ($0.04) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

386th out of 981 stocks

Surgical & Medical Instruments Industry

38th out of 97 stocks

See Top Rated MarketRank™ Stocks Here

AXNX stock logo

About Axonics (NASDAQ:AXNX) Stock

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

AXNX Stock News Headlines

May 31, 2023 | markets.businessinsider.com
Jefferies Sticks to Its Hold Rating for Axonics Modulation Technologies (AXNX)
May 31, 2023 | finance.yahoo.com
Even though Axonics (NASDAQ:AXNX) has lost US$173m market cap in last 7 days, shareholders are still up 28% over 3 years
June 8, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
May 23, 2023 | markets.businessinsider.com
Where Axonics Stands With Analysts
May 23, 2023 | americanbankingnews.com
CL King Begins Coverage on Axonics (NASDAQ:AXNX)
May 18, 2023 | americanbankingnews.com
Axonics, Inc. (NASDAQ:AXNX) Receives $78.88 Consensus PT from Brokerages
May 16, 2023 | finance.yahoo.com
What Makes Axonics (AXNX) Unique?
May 12, 2023 | seekingalpha.com
Axonics: Attractive Strong Growth Profile
June 8, 2023 | Chaikin Analytics (Ad)
Wall Street Veteran: "A New Wave of Crashes Will Rock US Stocks"
He called the 2020 crash and 2022 bear market. Now he says the next 90 days will determine your financial life for a decade. It doesn't matter if you have money in stocks right now, or are waiting on the sidelines. The short period we're about to enter changes everything.
May 8, 2023 | finance.yahoo.com
A Look At The Intrinsic Value Of Axonics, Inc. (NASDAQ:AXNX)
May 6, 2023 | americanbankingnews.com
Axonics (NASDAQ:AXNX) Price Target Raised to $73.00 at Needham & Company LLC
May 4, 2023 | seekingalpha.com
Axonics: Q1 Fall Provides Great Entry Point
April 30, 2023 | americanbankingnews.com
Axonics (NASDAQ:AXNX) vs. DexCom (NASDAQ:DXCM) Financial Analysis
April 30, 2023 | americanbankingnews.com
Axonics (AXNX) Scheduled to Post Earnings on Monday
April 26, 2023 | americanbankingnews.com
Danny L. Dearen Sells 2,001 Shares of Axonics, Inc. (NASDAQ:AXNX) Stock
April 25, 2023 | finance.yahoo.com
Axonics to Participate in Upcoming Investor Conferences
April 24, 2023 | finance.yahoo.com
Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation
April 23, 2023 | americanbankingnews.com
Brokerages Set Axonics, Inc. (NASDAQ:AXNX) PT at $78.63
April 19, 2023 | americanbankingnews.com
Truist Financial Cuts Axonics (NASDAQ:AXNX) Price Target to $73.00
April 17, 2023 | finance.yahoo.com
Investors Interested In Axonics, Inc.'s (NASDAQ:AXNX) Revenues
April 16, 2023 | americanbankingnews.com
Mizuho Begins Coverage on Axonics (NASDAQ:AXNX)
April 10, 2023 | finance.yahoo.com
Axonics to Report First Quarter 2023 Financial Results on May 1
April 10, 2023 | americanbankingnews.com
Head-To-Head Contrast: Axonics (NASDAQ:AXNX) versus Universal Media Group (OTCMKTS:UMGP)
April 6, 2023 | americanbankingnews.com
Danny L. Dearen Sells 15,000 Shares of Axonics, Inc. (NASDAQ:AXNX) Stock
March 31, 2023 | americanbankingnews.com
Axonics, Inc. (NASDAQ:AXNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
March 28, 2023 | americanbankingnews.com
Analyzing Universal Media Group (OTCMKTS:UMGP) & Axonics (NASDAQ:AXNX)
March 25, 2023 | americanbankingnews.com
Axonics (NASDAQ:AXNX) Stock Rating Upgraded by Needham & Company LLC
See More Headlines

AXNX Price History

AXNX Company Calendar

Last Earnings
5/01/2023
Today
6/07/2023
Next Earnings (Estimated)
8/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXNX
CUSIP
N/A
CIK
1603756
Web
www.axonics.com
Phone
(949) 396-6322
Fax
949-396-6321
Employees
610
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$78.44
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$73.00
Forecasted Upside/Downside
+54.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.99)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-59,700,000.00
Net Margins
-15.64%
Pretax Margin
-16.42%
Return on Equity
-8.67%
Return on Assets
-7.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.10
Quick Ratio
6.10

Sales & Book Value

Annual Sales
$273.70 million
Price / Sales
9.36
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.51 per share
Price / Book
4.42

Miscellaneous

Outstanding Shares
50,380,000
Free Float
49,220,000
Market Cap
$2.56 billion
Optionable
Not Optionable
Beta
0.40

Key Executives

  • Mr. Raymond W. CohenMr. Raymond W. Cohen (Age 64)
    CEO & Director
    Comp: $1.71M
  • Mr. Danny L. DearenMr. Danny L. Dearen (Age 60)
    Pres & CFO
    Comp: $799.08k
  • Mr. Rinda K. SamaMr. Rinda K. Sama (Age 44)
    Chief Operating Officer
    Comp: $902.83k
  • Dr. John Woock Ph.D. (Age 40)
    Exec. VP, Chief Marketing & Strategy Officer
    Comp: $902.83k
  • Mr. Alfred J. Ford Jr.Mr. Alfred J. Ford Jr. (Age 52)
    Chief Commercial Officer
    Comp: $902.96k
  • Mr. Guangqiang Jiang Ph.D. (Age 49)
    Chief Technology Officer
  • Mr. Neil Bhalodkar
    VP of Investor Relations
  • Mr. Aaron Pettit
    Gen. Counsel & Chief Compliance Officer
  • Mr. Michael V. Williamson Esq. (Age 51)
    J.D., Sr. VP, Gen. & IP Counsel
  • Dr. Karen L. Noblett M.A.S. (Age 60)
    M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AXNX Stock - Frequently Asked Questions

Should I buy or sell Axonics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXNX shares.
View AXNX analyst ratings or view top-rated stocks.

What is Axonics' stock price forecast for 2023?

9 brokerages have issued twelve-month price targets for Axonics' shares. Their AXNX share price forecasts range from $73.00 to $90.00. On average, they predict the company's share price to reach $78.44 in the next twelve months. This suggests a possible upside of 54.3% from the stock's current price.
View analysts price targets for AXNX or view top-rated stocks among Wall Street analysts.

How have AXNX shares performed in 2023?

Axonics' stock was trading at $62.53 at the beginning of 2023. Since then, AXNX stock has decreased by 18.7% and is now trading at $50.85.
View the best growth stocks for 2023 here.

When is Axonics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our AXNX earnings forecast.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) released its earnings results on Monday, May, 1st. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.10. The firm earned $70.65 million during the quarter, compared to the consensus estimate of $65.03 million. Axonics had a negative net margin of 15.64% and a negative trailing twelve-month return on equity of 8.67%. The firm's revenue was up 45.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.50) EPS.

What ETFs hold Axonics' stock?

ETFs with the largest weight of Axonics (NASDAQ:AXNX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Neuberger Berman Disrupters ETF (NBDS), Fidelity Digital Health ETF (FDHT), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Nuveen Small Cap Select ETF (NSCS), Principal Healthcare Innovators ETF (BTEC) and Goldman Sachs Future Health Care Equity ETF (GDOC).

What guidance has Axonics issued on next quarter's earnings?

Axonics issued an update on its FY 2023 earnings guidance on Monday, May, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $348.00 million-$348.00 million, compared to the consensus revenue estimate of $343.77 million.

What is Raymond W. Cohen's approval rating as Axonics' CEO?

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

(AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Axonics' stock symbol?

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

Who are Axonics' major shareholders?

Axonics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.15%), FMR LLC (5.16%), AXA S.A. (3.32%), Champlain Investment Partners LLC (2.65%), Hood River Capital Management LLC (2.60%) and State Street Corp (2.23%). Insiders that own company stock include Alfred J Ford Jr, Alfred J Ford, Jr, Bakker Juliet Tammenoms, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends.

How do I buy shares of Axonics?

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axonics' stock price today?

One share of AXNX stock can currently be purchased for approximately $50.85.

How much money does Axonics make?

Axonics (NASDAQ:AXNX) has a market capitalization of $2.56 billion and generates $273.70 million in revenue each year. The company earns $-59,700,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis.

How many employees does Axonics have?

The company employs 610 workers across the globe.

How can I contact Axonics?

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The official website for the company is www.axonics.com. The company can be reached via phone at (949) 396-6322, via email at ir@axonics.com, or via fax at 949-396-6321.

This page (NASDAQ:AXNX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -